Psoriasis (PsO)

Immunology
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

SFA Therapeutics
SFA TherapeuticsPA - Jenkintown
1 program
1
SFA002Phase 2/31 trial
Active Trials
NCT06863493Not Yet RecruitingEst. Sep 2026
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Biologic AgentN/A1 trial
Active Trials
NCT07132333Recruiting3,000Est. Nov 2032

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
SFA TherapeuticsSFA002
Heidelberg PharmaBiologic Agent

Clinical Trials (2)

Total enrollment: 3,000 patients across 2 trials

Comparison of Otezla to SFA-002 to Placebo in Plaque Psoriasis Patients

Start: Jun 2025Est. completion: Sep 2026
Phase 2/3Not Yet Recruiting

Molecular Inflammation Board at the Center for Personalized Medicine

Start: Nov 2022Est. completion: Nov 20323,000 patients
N/ARecruiting

Related Jobs in Immunology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 3,000 patients
2 companies competing in this space